86.91 -0.07 (-0.08%)
Pre-Market: 7:01AM EST
|Bid||86.51 x 500|
|Ask||87.84 x 100|
|Day's Range||86.03 - 87.41|
|52 Week Range||74.00 - 89.09|
|PE Ratio (TTM)||41.40|
|Forward Dividend & Yield||2.25 (2.59%)|
|1y Target Est||N/A|
Outcomes on these three clinical trials in diabetes this year could change the way the disease is treated going into the next decade.
Eli Lilly (LLY) animal health unit Elanco and partner Aratana announce the EU approval of Galliprant for treatment of pain associated with osteoarthritis in dogs.
What's Lilly's next stage of growth? CEO Dave Ricks answered this question and more at the J.P. Morgan Healthcare Conference.
Alex Azar, a former drug industry executive and lobbyist nominated to run the U.S. Department of Health and Human Services, indicated on Tuesday he supported a Republican bid to overhaul Medicaid and again vowed to tackle high drug prices. Azar appeared before the Senate Finance Committee on Tuesday, which will ultimately decide whether to move his nomination forward. Azar also vowed to uphold Obamacare as long as it remained the law but said that the program needed changes.
WASHINGTON (AP) — Empowering Medicare to negotiate drug prices could leave patients with reduced access to medications, President Donald Trump's pick for health secretary warned Tuesday.
As we discussed earlier, Incyte (INCY) reported revenue of $381.5 million in 3Q17, a 41.6% rise over its revenue of $269.5 million in 3Q16. This revenue growth was driven by increased demand for the drug Jakafi. The above graph shows a revenue breakup for Incyte over the last few quarters.
AbbVie (ABBV) is focused on expanding Risankizumab’s label for multiple indications such as psoriatic arthritis, ulcerative colitis, and Crohn’s disease. The company expects to witness a significant rise in demand for Crohn’s disease and ulcerative colitis patients, mainly driven by increasing diagnosis rates and the greater prevalence of patients already treated with biologics.
Efforts to find treatments for Alzheimer’s disease suffered blows in recent days, but many companies, scientists and investors are still optimistic that they can find a way to treat the memory-robbing ...
Eli Lilly & Co. Chief Executive Officer Dave Ricks said on Monday that the recent changes in U.S. tax policy will help the drugmaker lower its global tax burden as he continues to look for deals in areas ...
The law makes it cheaper for multinational companies to repatriate foreign cash, and they could use that money to fund deals.
Pfizer (PFE) will reportedly end R&D efforts in Alzheimer's and Parkinson's disease areas, which will result in about 300 job cuts.
In December 2017, the U.S. FDA (Food and Drug Administration) approved Novo Nordisk’s (NVO) Ozempic as an addition to diet and exercise for the improvement of blood sugar levels in individuals with type ...
With pharma major, Pfizer (PFE), announcing its intention to drop plans to develop treatments for Alzheimer's and certain other disease areas, here is a look at what is going on in this corner of the market.
If an 8-percent quarterly dividend increase is any indication, Eli Lilly and Co (NYSE: LLY ) is confident of its growth potential. Its optimism echoes with one Wall Street analyst. The Rating Argus analyst ...
In 3Q17, Novo Nordisk’s (NVO) Victoza reported revenues of 5.3 billion Danish krone (or DKK), which reflected ~9% growth on a year-over-year (or YoY) basis.
Johnson & Johnson (NYSE:JNJ) has remained a long-time favorite among conservative investors. One is hard-pressed to find many negatives about Johnson & Johnson stock. Of all the stocks traded today, few have enjoyed so much cash flow, so consistently, for so long as Johnson & Johnson.
In 3Q17, Novo Nordisk’s (NVO) new generation insulin generated revenues of 2.1 billion Danish krone (or DKK), which reflected ~93% growth on a year-over-year (or YoY) basis.
Jan.09 -- David Ricks, chairman and chief executive officer at Eli Lilly & Co., discusses pricing pressures, the drug Trulicity, and the company's commitment to diabetes research. He speaks with Erik Schatzker on "Bloomberg Markets" from the JPMorgan Health Care conference in San Francisco.
Jan.09 -- David Ricks, chairman and chief executive officer at Eli Lilly & Co., discusses drug pricing and shifting industry dynamics. He speaks with Erik Schatzker on "Bloomberg Markets" from the JPMorgan Healthcare Conference in San Francisco.
At the J.P. Morgan Health Care Conference, Eli Lilly CEO David Ricks speaks to CNBC's Meg Tirrell about the state of health care this year, drug pricing and the impact of tax reform on the pharmaceutical industry.